| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head Injuries, Penetrating | 8 | 2023 | 55 | 3.040 |
Why?
|
| Brain Injuries | 8 | 2023 | 164 | 2.120 |
Why?
|
| Inpatients | 4 | 2021 | 310 | 1.690 |
Why?
|
| Emergency Service, Hospital | 4 | 2021 | 521 | 1.680 |
Why?
|
| Cerebral Hemorrhage | 11 | 2022 | 338 | 1.580 |
Why?
|
| Stroke | 8 | 2024 | 982 | 1.550 |
Why?
|
| Brain Injuries, Traumatic | 5 | 2023 | 99 | 1.280 |
Why?
|
| Brain Death | 5 | 2023 | 82 | 1.270 |
Why?
|
| Brain Ischemia | 4 | 2020 | 399 | 1.210 |
Why?
|
| Intracranial Pressure | 4 | 2023 | 87 | 1.020 |
Why?
|
| Family | 2 | 2023 | 325 | 0.960 |
Why?
|
| Intracranial Hypertension | 3 | 2023 | 57 | 0.910 |
Why?
|
| Thrombolytic Therapy | 4 | 2021 | 232 | 0.900 |
Why?
|
| Intracranial Hemorrhages | 3 | 2020 | 129 | 0.860 |
Why?
|
| Wounds, Gunshot | 2 | 2020 | 90 | 0.810 |
Why?
|
| Vascular System Injuries | 1 | 2021 | 30 | 0.760 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2020 | 4 | 0.760 |
Why?
|
| Hypopituitarism | 1 | 2020 | 19 | 0.750 |
Why?
|
| Adrenal Insufficiency | 1 | 2020 | 23 | 0.750 |
Why?
|
| Intracranial Thrombosis | 1 | 2020 | 27 | 0.700 |
Why?
|
| Neurologic Examination | 1 | 2020 | 120 | 0.690 |
Why?
|
| Thrombectomy | 2 | 2024 | 172 | 0.670 |
Why?
|
| Hypothyroidism | 1 | 2020 | 238 | 0.640 |
Why?
|
| Ischemic Attack, Transient | 1 | 2020 | 182 | 0.630 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 167 | 0.630 |
Why?
|
| Retrospective Studies | 19 | 2024 | 9003 | 0.580 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 270 | 0.500 |
Why?
|
| Humans | 58 | 2024 | 89063 | 0.460 |
Why?
|
| Hematoma | 3 | 2021 | 108 | 0.390 |
Why?
|
| Hypoxia-Ischemia, Brain | 2 | 2022 | 52 | 0.390 |
Why?
|
| Injury Severity Score | 2 | 2021 | 143 | 0.360 |
Why?
|
| Neurosurgical Procedures | 5 | 2023 | 232 | 0.330 |
Why?
|
| Cryotherapy | 1 | 2009 | 30 | 0.330 |
Why?
|
| Body Temperature Regulation | 1 | 2009 | 56 | 0.330 |
Why?
|
| Middle Aged | 26 | 2024 | 25863 | 0.310 |
Why?
|
| Prognosis | 7 | 2021 | 3773 | 0.310 |
Why?
|
| Fever | 1 | 2009 | 128 | 0.300 |
Why?
|
| Brain Stem | 4 | 2020 | 167 | 0.300 |
Why?
|
| Brain Edema | 3 | 2020 | 58 | 0.290 |
Why?
|
| Aged | 17 | 2024 | 19077 | 0.270 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2008 | 138 | 0.270 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 159 | 0.270 |
Why?
|
| Treatment Outcome | 12 | 2024 | 8203 | 0.260 |
Why?
|
| Neurology | 2 | 2017 | 74 | 0.260 |
Why?
|
| Time Factors | 5 | 2021 | 5320 | 0.260 |
Why?
|
| Male | 26 | 2024 | 42251 | 0.250 |
Why?
|
| Female | 30 | 2024 | 46011 | 0.250 |
Why?
|
| Heart Arrest | 2 | 2022 | 279 | 0.240 |
Why?
|
| Intensive Care Units | 3 | 2023 | 395 | 0.230 |
Why?
|
| Coma | 2 | 2021 | 47 | 0.230 |
Why?
|
| Critical Care | 3 | 2017 | 380 | 0.230 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 433 | 0.220 |
Why?
|
| Decompressive Craniectomy | 1 | 2023 | 18 | 0.210 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1715 | 0.210 |
Why?
|
| Seizures | 2 | 2020 | 306 | 0.200 |
Why?
|
| Intracranial Aneurysm | 3 | 2020 | 175 | 0.200 |
Why?
|
| Models, Biological | 1 | 2009 | 1763 | 0.200 |
Why?
|
| Length of Stay | 2 | 2023 | 732 | 0.190 |
Why?
|
| Neurosurgery | 2 | 2021 | 99 | 0.190 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2021 | 12 | 0.190 |
Why?
|
| Head Injuries, Closed | 1 | 2020 | 12 | 0.190 |
Why?
|
| Hospitalization | 3 | 2021 | 876 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2024 | 262 | 0.190 |
Why?
|
| Hypocalcemia | 1 | 2020 | 41 | 0.180 |
Why?
|
| Pituitary-Adrenal System | 1 | 2020 | 64 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2022 | 4273 | 0.180 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2020 | 17 | 0.180 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 81 | 0.180 |
Why?
|
| Triage | 1 | 2021 | 111 | 0.180 |
Why?
|
| Apnea | 1 | 2020 | 31 | 0.180 |
Why?
|
| Hemostatics | 1 | 2021 | 57 | 0.180 |
Why?
|
| Heuristics | 1 | 2020 | 15 | 0.180 |
Why?
|
| Heart Conduction System | 1 | 2021 | 112 | 0.180 |
Why?
|
| Prevalence | 3 | 2021 | 1240 | 0.180 |
Why?
|
| Amantadine | 1 | 2020 | 18 | 0.180 |
Why?
|
| Nootropic Agents | 1 | 2020 | 10 | 0.180 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 93 | 0.180 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 66 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2021 | 2657 | 0.170 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 143 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 149 | 0.170 |
Why?
|
| Cognition Disorders | 2 | 2020 | 235 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 1043 | 0.170 |
Why?
|
| Heart Rate | 3 | 2021 | 493 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 197 | 0.170 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 17 | 0.170 |
Why?
|
| Caregivers | 1 | 2021 | 159 | 0.170 |
Why?
|
| Respiratory Therapy | 1 | 2019 | 14 | 0.170 |
Why?
|
| Thyroid Gland | 1 | 2020 | 280 | 0.160 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2020 | 168 | 0.160 |
Why?
|
| Incidence | 3 | 2020 | 1592 | 0.160 |
Why?
|
| Electroencephalography | 1 | 2023 | 749 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 599 | 0.160 |
Why?
|
| Survivors | 1 | 2020 | 233 | 0.160 |
Why?
|
| Drug Therapy | 1 | 2019 | 70 | 0.160 |
Why?
|
| Acute Disease | 1 | 2020 | 841 | 0.160 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 214 | 0.160 |
Why?
|
| Electrocardiography | 1 | 2021 | 493 | 0.160 |
Why?
|
| Hospitals, University | 1 | 2019 | 195 | 0.160 |
Why?
|
| Thrombocytosis | 1 | 2018 | 8 | 0.160 |
Why?
|
| Plateletpheresis | 1 | 2018 | 2 | 0.160 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2018 | 5 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 187 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 148 | 0.150 |
Why?
|
| Patient Readmission | 1 | 2022 | 351 | 0.150 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 2362 | 0.150 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 345 | 0.150 |
Why?
|
| Chicago | 2 | 2020 | 1423 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 280 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2020 | 779 | 0.150 |
Why?
|
| Action Potentials | 1 | 2021 | 596 | 0.150 |
Why?
|
| Adult | 18 | 2024 | 26507 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1706 | 0.130 |
Why?
|
| Disease Management | 1 | 2018 | 329 | 0.130 |
Why?
|
| Societies, Medical | 2 | 2017 | 570 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.130 |
Why?
|
| Macroglossia | 1 | 2014 | 2 | 0.120 |
Why?
|
| Brain | 4 | 2013 | 2281 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 250 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2752 | 0.110 |
Why?
|
| Pregnatrienes | 3 | 2007 | 14 | 0.110 |
Why?
|
| Glasgow Coma Scale | 2 | 2023 | 73 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 47 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2021 | 2290 | 0.110 |
Why?
|
| Subarachnoid Hemorrhage, Traumatic | 1 | 2012 | 3 | 0.110 |
Why?
|
| Ammonia | 1 | 2011 | 38 | 0.100 |
Why?
|
| Neuromuscular Diseases | 1 | 2012 | 31 | 0.100 |
Why?
|
| Hyperammonemia | 1 | 2011 | 13 | 0.100 |
Why?
|
| Hepatic Encephalopathy | 1 | 2011 | 39 | 0.100 |
Why?
|
| Risk Factors | 6 | 2022 | 5466 | 0.100 |
Why?
|
| Hypothermia, Induced | 1 | 2011 | 82 | 0.090 |
Why?
|
| Hospitals | 1 | 2013 | 299 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2013 | 490 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 162 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2012 | 265 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 315 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2021 | 291 | 0.090 |
Why?
|
| Machine Learning | 2 | 2022 | 257 | 0.080 |
Why?
|
| Blood Physiological Phenomena | 1 | 2009 | 9 | 0.080 |
Why?
|
| Ice | 1 | 2009 | 11 | 0.080 |
Why?
|
| Quadriplegia | 1 | 2008 | 23 | 0.080 |
Why?
|
| Hernia | 1 | 2008 | 23 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 833 | 0.080 |
Why?
|
| Sodium Chloride | 1 | 2009 | 88 | 0.080 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2011 | 223 | 0.080 |
Why?
|
| Cold Temperature | 1 | 2009 | 160 | 0.080 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2007 | 1 | 0.080 |
Why?
|
| Eye Movements | 1 | 2008 | 119 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 434 | 0.080 |
Why?
|
| Encephalitis | 1 | 2008 | 104 | 0.080 |
Why?
|
| Tremor | 1 | 2007 | 22 | 0.070 |
Why?
|
| Aneurysm, Ruptured | 1 | 2007 | 54 | 0.070 |
Why?
|
| Fingers | 1 | 2007 | 69 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2007 | 125 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 967 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 781 | 0.070 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 6777 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 771 | 0.060 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2005 | 3 | 0.060 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 2005 | 4 | 0.060 |
Why?
|
| Torticollis | 1 | 2005 | 11 | 0.060 |
Why?
|
| Dystonic Disorders | 1 | 2005 | 7 | 0.060 |
Why?
|
| Botulinum Toxins | 1 | 2005 | 17 | 0.060 |
Why?
|
| Patient Admission | 2 | 2021 | 114 | 0.060 |
Why?
|
| Craniotomy | 1 | 2005 | 88 | 0.060 |
Why?
|
| Decompression, Surgical | 1 | 2005 | 87 | 0.060 |
Why?
|
| Vasospasm, Intracranial | 1 | 2004 | 35 | 0.060 |
Why?
|
| Minority Groups | 1 | 2005 | 144 | 0.060 |
Why?
|
| Radial Artery | 1 | 2024 | 33 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2021 | 2863 | 0.060 |
Why?
|
| Neurophysiological Monitoring | 1 | 2023 | 17 | 0.060 |
Why?
|
| Catheters | 1 | 2024 | 76 | 0.060 |
Why?
|
| Adolescent | 5 | 2023 | 9237 | 0.060 |
Why?
|
| Latin America | 1 | 2023 | 13 | 0.050 |
Why?
|
| Disease Progression | 2 | 2021 | 1488 | 0.050 |
Why?
|
| Income | 1 | 2023 | 83 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2023 | 53 | 0.050 |
Why?
|
| Death | 1 | 2023 | 85 | 0.050 |
Why?
|
| Swine | 1 | 2023 | 581 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2023 | 227 | 0.050 |
Why?
|
| Cranial Fossa, Posterior | 2 | 2014 | 25 | 0.050 |
Why?
|
| Resuscitation | 1 | 2022 | 109 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 266 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1591 | 0.050 |
Why?
|
| Electrolytes | 1 | 2020 | 52 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 172 | 0.050 |
Why?
|
| Life Support Care | 1 | 2021 | 50 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2007 | 1714 | 0.040 |
Why?
|
| Young Adult | 2 | 2023 | 6288 | 0.040 |
Why?
|
| Spinal Injuries | 1 | 2020 | 21 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2021 | 117 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2020 | 78 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2013 | 299 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 2020 | 56 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 331 | 0.040 |
Why?
|
| Patient Participation | 1 | 2021 | 224 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 77 | 0.040 |
Why?
|
| Snoring | 2 | 1996 | 12 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2020 | 118 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 251 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 212 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 292 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 386 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 469 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 322 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2021 | 426 | 0.040 |
Why?
|
| Glasgow Outcome Scale | 2 | 2007 | 7 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 850 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1063 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2014 | 105 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 625 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1140 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2020 | 398 | 0.030 |
Why?
|
| Decision Making | 1 | 2021 | 665 | 0.030 |
Why?
|
| Neuroprotective Agents | 2 | 2007 | 100 | 0.030 |
Why?
|
| Catalepsy | 1 | 1994 | 3 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 1996 | 117 | 0.030 |
Why?
|
| Benzhydryl Compounds | 1 | 1994 | 44 | 0.030 |
Why?
|
| Primary Dysautonomias | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2014 | 18 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1755 | 0.030 |
Why?
|
| Amines | 1 | 2014 | 28 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 121 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2014 | 85 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2014 | 45 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 18 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2014 | 344 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 1994 | 218 | 0.030 |
Why?
|
| Abdomen | 1 | 1992 | 122 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2008 | 3443 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2012 | 102 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2011 | 83 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 135 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 138 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1991 | 53 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 345 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 287 | 0.020 |
Why?
|
| Child | 1 | 2022 | 7149 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 809 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 1 | 1991 | 131 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2011 | 524 | 0.020 |
Why?
|
| United States | 1 | 2023 | 6955 | 0.020 |
Why?
|
| Hypertension | 1 | 1996 | 741 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 27317 | 0.020 |
Why?
|
| Pons | 1 | 2008 | 25 | 0.020 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2008 | 10 | 0.020 |
Why?
|
| Sleep | 1 | 1992 | 452 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2008 | 104 | 0.020 |
Why?
|
| Prednisone | 1 | 2008 | 258 | 0.020 |
Why?
|
| Toes | 1 | 2007 | 14 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 449 | 0.020 |
Why?
|
| Oxygen | 1 | 1992 | 742 | 0.020 |
Why?
|
| Hypoxia | 1 | 1992 | 650 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2007 | 200 | 0.020 |
Why?
|
| Mandibular Diseases | 1 | 2005 | 16 | 0.020 |
Why?
|
| Mouth Diseases | 1 | 2005 | 16 | 0.020 |
Why?
|
| Wakefulness | 2 | 1996 | 135 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3209 | 0.020 |
Why?
|
| Posture | 1 | 2005 | 124 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2004 | 197 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1992 | 2275 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 3657 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 11737 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 3717 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1996 | 47 | 0.010 |
Why?
|
| Sex Ratio | 1 | 1996 | 23 | 0.010 |
Why?
|
| Sleep Stages | 1 | 1996 | 47 | 0.010 |
Why?
|
| Polysomnography | 1 | 1996 | 151 | 0.010 |
Why?
|
| Arousal | 1 | 1996 | 170 | 0.010 |
Why?
|
| Fatigue | 1 | 1996 | 179 | 0.010 |
Why?
|
| Placebos | 1 | 1994 | 214 | 0.010 |
Why?
|
| Respiration | 1 | 1996 | 267 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 1996 | 249 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1994 | 389 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1996 | 771 | 0.010 |
Why?
|
| Oximetry | 1 | 1992 | 82 | 0.010 |
Why?
|
| France | 1 | 1991 | 48 | 0.010 |
Why?
|
| Age Factors | 1 | 1996 | 1867 | 0.010 |
Why?
|
| Drug Utilization | 1 | 1991 | 65 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1994 | 899 | 0.010 |
Why?
|
| Anxiety | 1 | 1991 | 308 | 0.010 |
Why?
|
| Depression | 1 | 1991 | 503 | 0.000 |
Why?
|